Executive Order Sparks New Phase for Psychedelic Biotech, but Risks Remain
Apr 24, 2026 09:00AM PST
Dan Ahrens of AdvisorShares shares how a new US executive order is reshaping the psychedelic biotech landscape by boosting stocks, but keeping investment risks alive.
